Tag Archives: AbbVie

AbbVie targets psychedelic-based depression drug market with $1.2 billion deal  Reuters AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline  PR Newswire AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug  Yahoo Finance AbbVie to buy Gilgamesh’s psychedelic drug for up to $1.2 billion  statnews.com AbbVie to buy psychedelic drug from partner Gilgamesh  Endpoints News Source link

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline Gilgamesh’s lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is a novel, short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser. NORTH CHICAGO, Ill. and NEW YORK, Aug. …

AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. New $195 million facility will further enhance AbbVie’s active pharmaceutical ingredient (API) production capacity and capabilities in the U.S. Expansion is part of AbbVie’s previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade Construction will begin in fall 2025 …

AbbVie Stock Pops After Earnings. What’s Driving Shares Higher.  Barron’s AbbVie sees no outsized tariff exposure, boosts profit forecast  Yahoo Finance AbbVie in charts: Revenues from Humira -58%, Skyrizi +62%, Rinvoq +42% Y/Y (ABBV:NYSE)  Seeking Alpha Is ABBV Stock (ABBV) a Buy Ahead of Q2 Earnings?  TipRanks Why AbbVie Stock Slumped Today  The Motley Fool Source link